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Over 130 X-linked genes have been robustly associated with developmental disorders, and X-
linked causes have been hypothesised to underlie the higher developmental disorder rates in
males. Here, we evaluate the burden of X-linked coding variation in 11,044 developmental
disorder patients, and find a similar rate of X-linked causes in males and females (6.0% and
6.9%, respectively), indicating that such variants do not account for the 1.4-fold male bias.
We develop an improved strategy to detect X-linked developmental disorders and identify
23 significant genes, all of which were previously known, consistent with our inference that
the vast majority of the X-linked burden is in known developmental disorder-associated
genes. Importantly, we estimate that, in male probands, only 13% of inherited rare missense
variants in known developmental disorder-associated genes are likely to be pathogenic. Our
results demonstrate that statistical analysis of large datasets can refine our understanding of
modes of inheritance for individual X-linked disorders.
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everal attributes of X-chromosomal biology render it unique
among chromosomes, and have profoundly influenced the
landscape of X-linked monogenic disorders. The hemi-
zygosity of the X chromosome in males results in a distinctive
male-specific pattern of segregation in pedigrees for X-linked
recessive disorders, which has facilitated the recognition of such
disorders and catalysed the identification of the underlying
associated genes1. By contrast, X-linked dominant disorders do
not result in such characteristic segregation patterns in pedigrees,
and are expected predominantly in females due to the con-
siderably lower mutation rate of the maternally-inherited X
chromosome in males2.
While most X-linked disorders exhibit a profound sex-bias,
suggestive of the underlying mode of inheritance, it is frequently
observed that both sexes can manifest the same disorder. There
are several possible explanations, which are not mutually exclu-
sive. Skewing of X chromosome inactivation in females (which
normally achieves dosage compensation) provides a mechanism
for some female carriers of pathogenic variations in X-linked
recessive genes to manifest disease of varying severity levels,
although extreme skewing is rare on a population level3,4; this
mechanism has previously been inferred to occur in 7.6% of
female patients with intellectual disability5. One alternative
explanation is an incompletely penetrant dominant phenotype
associated with a variant that is fully penetrant when hemizygous;
a special case of this is semi-dominance, in which heterozygous
females are affected but hemizygous males are seldom observed
due to lethality. Another explanation is that a disorder is truly
dominant such that the hemizygous and heterozygous pheno-
types are identical. These complexities have led some to recom-
mend that the field refer collectively to ‘X-linked disorders’,
avoiding explicit classification based on their individual modes of
inheritance6,7. Nonetheless, X-linked Mendelian disease genes are
often classified as ‘X-linked recessive’ (XLR) or ‘X-linked domi-
nant’ (XLD) e.g. by the Online Mendelian Inheritance in Man
catalog (OMIM; https://omim.org/).
The majority of X-linked monogenic disorders that have been
identified are DDs, especially neurodevelopmental disorders such
as intellectual disability (ID). The highly-curated DDG2P
(Developmental Disorder Gene-to-Phenotype) database8 contains
over 130 DD-associated genes on the X chromosome, most of
which are observed predominantly in males and are presumed X-
linked recessive disorders, which can be caused by either de novo
mutations or maternally inherited variants. Analyses of new large
datasets of population variation have called into question a few of
these gene associations9, although most remain robust. Impor-
tantly, mutations in the same gene can cause more than one
condition: 39 of the 132 X-linked genes in DDG2P are associated
with more than one syndrome, many of them with different
modes of inheritance and different mechanisms (e.g. loss-of-
function versus activating).
The recent availability of exome sequencing, large cohorts of
both cases and controls, and a fine-grained understanding of the
germline mutation rate10, have together empowered ‘burden’
analyses which can quantify the absolute and relative contribu-
tions of different classes of inherited and de novo variation to
particular disorders and subsets of patients11–14. It has been
suggested that the 1.3-fold male bias in the incidence of ID can be
largely attributed to the male-biased contribution of X-linked
disorders15,16, although this has not been formally demonstrated.
Here we analyse exome sequencing data from 11,044 families in
the Deciphering Developmental Disorders (DDD) study and
show that the relative contribution of X-linked causes of DDs is
similar in male and female probands. We estimate the relative
contribution of de novo versus inherited pathogenic variants in
males (finding 41% de novo overall, 36% in X-linked recessive
genes) and explore positive predictive values of different classes of
variants, showing that this is very low for inherited missense
variants in males. Furthermore, we develop an improved method
to detect X-linked disease genes which identifies 23 genes, all of
which have already been associated with DDs. Our study
demonstrates the value of large cohort-based burden analyses for
informing clinical practice and refining our understanding of
inheritance modes for X-linked disorders.
Results
Comparison of male versus female phenotypes in DDD. There
are 40% more male than female probands in the DDD study
(7844 males versus 5618 females), similar to the bias reported in
other ID/DD cohorts9, but lower than the four-fold male bias
reported in autism cohorts17. We compared the phenotypes of
male versus female probands in the study to explore whether
phenotypic differences might be contributing to recruitment bias
in males. Males were more likely to have another affected family
member than females (26.5% versus 21.0%; Fisher’s exact test p=
5 × 10−13). They tended to be recruited ~4.8 months earlier than
females (linear regression p= 0.0004), so we controlled for age at
assessment in the following tests of phenotypic differences. Males
had slightly more affected organ systems than females, although
this was only nominally significant (mean and ranges: 3.55 [1–12]
for males, 3.49 [1–11] for females; linear regression p= 0.049;
Supplementary Fig. 1). There were significant differences in the
prevalence of several phenotypic features between the sexes
(Supplementary Data 1). For example, after correcting for age at
assessment, males were 2.4-times more likely to have an
abnormality of the genitourinary system (logistic regression p=
1.3 × 10−48), 2.1-times more likely to have autistic behaviour (p
= 8 × 10−41), and 2.0-times more likely to show hyperactivity (p
= 7 × 10−10). However, none of these differences were large
enough in magnitude to suggest that they made a major con-
tribution to recruitment bias. Males in DDD were significantly
taller (linear regression p= 8 × 10−8) and had greater occipital
frontal circumference at recruitment (p= 4×10−17) than females
(measured relative to the sex- and age-adjusted distributions in
the general population) (Supplementary Table 1). Curiously, we
observed that males walked on average 1.2 months earlier than
females in the study (linear regression p= 2 × 10−7) (Supple-
mentary Table 1), although in the general population, they tend
to walk about two weeks later than females on average18. This
may correspond with the observation that females in the cohort
are slightly more likely than males to have severe ID/DD (12.4%
versus 10.9%; logistic regression p= 0.02) but equally likely to
have mild or moderate ID/DD (Supplementary Data 1). These
comparisons suggest that although there are some significant
differences in average phenotypes between the sexes in DDD,
these are small in magnitude and males and females are broadly
similar in clinical presentation.
X chromosome burden analysis. We hypothesised that the
higher number of males in DDD might be due to variation on the
X chromosome, since males, being haploid, might be more vul-
nerable to pathogenic variants on this chromosome and could be
affected by both de novo and maternally inherited variants. To
avoid biases that would be introduced by considering only
diagnoses in known DD genes, we carried out a sex-specific
burden analysis to estimate the fraction of patients attributable to
rare or de novo coding variants in all genes in the non-
pseudoautosomal regions of the X chromosome, assuming a
monogenic model with full penetrance. We focused on 7136
independent male probands (5138 in family trios) and 3908
independent female probands in trios, and considered variants
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20852-3
2 NATURE COMMUNICATIONS |          (2021) 12:627 | https://doi.org/10.1038/s41467-020-20852-3 | www.nature.com/naturecommunications
with minor allele frequency <0.1% and with no hemizygotes in
the gnomAD resource of population variation19. In male pro-
bands, we performed a case/control analysis, comparing probands
to 8551 unaffected DDD fathers. This analysis implicitly includes
both inherited variants and DNMs. For the purposes of some
analyses, we also conducted an enrichment analysis of DNMs
alone in the male trio probands, with quality control optimised to
detect DNMs (Supplementary Data 2), and compared to a null
mutation model10. In female trio probands, we performed a
DNM enrichment analysis, assuming that there would be very
few inherited pathogenic variants on the X chromosome in
females since the vast majority of parents are unaffected. We are
thus assuming full penetrance in females.
Overall, we estimated from the burden analysis that 6.0% of
males (95% confidence interval [3.6–8.6%]) and 6.9% of females
[5.9–7.9%] had a pathogenic X-linked protein-truncating or
missense/inframe variant (Fig. 1a). This implies that monogenic
X-linked coding causes of DDs are not the cause of the male bias
in DDD. In females, 90% [83–97%] of the burden was in DD-
associated genes, versus 63% [44–100%] in males (95%
confidence intervals from bootstrapping shown in Supplementary
Fig. 2A, B). In trio males, 41% [23–100%] of the burden was de
novo and the rest inherited (Supplementary Fig. 2C). Of the 127
de novo PTVs or missense/inframe mutations observed in males,
eight (6%) appeared mosaic in mothers, and 12 (9%) post-zygotic
mosaic in the probands.
The relative contribution of missense/inframe variants was
higher in males than females, but not significantly so (Fig. 1a).
Overall, 38.9% of the X-linked exonic burden was driven by
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Fig. 1 Results from burden analysis of rare and de novo coding variants on the X chromosome. a Fraction of males and females attributable to rare
inherited and de novo coding variants on the X chromosome. Note that in the males, the overall attributable fraction was estimated from the case/control
analysis of all male probands (7136 cases versus 8551 controls), whereas that for de novo mutations (DNMs) was estimated only in the 5138 male trio
probands. In the females, only de novos were considered since we were assuming full penetrance. b Relative fraction of protein-truncating variants (PTVs)
versus missense/inframe variants amongst ClinVar likely pathogenic or pathogenic variants in X-linked DDG2P genes, versus the fraction inferred in the burden
analysis in DDD. c Estimated attributable fraction versus positive predictive value for DNMs and inherited variants in males in X-linked DDG2P genes. Inherited
missense variants are split according to CADD (Combined Annotation Dependent Depletion) 21 and MPC (missense badness, PolyPhen, constraint) 22 scores.
In a, c the coloured bars (a) or points (c) show the point estimate and the error bars show 95% confidence intervals calculated as described in the ‘Methods’.
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inframe (Fig. 1b). In contrast, in a set of 3906 variants in X-linked
DD-associated genes reported as ‘pathogenic’ or ‘likely patho-
genic’ in ClinVar20, 60.6% were PTVs and 39.4% were missense/
inframe variants. This is significantly different from our burden
analysis of DD-associated X-linked genes (Fisher’s exact test p=
5 × 10−21; Fig. 1b), and likely reflects the fact that PTVs are easier
to interpret and hence more likely to be considered pathogenic or
likely pathogenic by clinical geneticists and genetic diagnostic
laboratories.
We next estimated the fraction of the observed rare inherited
or de novo variants in known X-linked DD genes were actually
likely to be pathogenic (i.e. the positive predictive value, PPV)
(Fig. 1c). These PPVs can assist accurate diagnostic interpretation
by providing prior probabilities of pathogenicity for different
classes of variation. For de novo PTVs, de novo missense
mutations and inherited rare PTVs in males, the PPV was >80%.
However, the PPV for inherited rare missense variants (MAF <
0.001) that were not observed as hemizygotes in gnomAD was
estimated to be only 13.2% [3.9–21.5%], indicating that there is a
substantial risk of incorrect diagnosis and hence clinical
mismanagement. In line with this, of variants passing these
filters that have been reported in DECIPHER and rated by
clinicians, 56/272 (20.6% [15.9–25.9%]) were classed as patho-
genic or likely pathogenic, and 47.8% as ‘uncertain’ [41.7–53.9%].
If we did not apply the additional filter requiring zero
hemizygotes in gnomAD in our burden analysis, the PPV was
not significantly different from 0, although it increased to 15.6%
[5.4–24.6%] if we reduced the MAF filter from 0.1% to 0.005%
(Supplementary Fig. 3). We were able to increase the PPV to
~60% by applying more stringent filters on CADD21 and MPC22
scores to the missense variants (Fig. 1c), indicating that such
filters are likely to aid clinical genetics practice by reducing rates
of incorrect assignment of pathogenicity. However, Fig. 1c also
shows that this improvement in specificity is counterbalanced by
some reduction in sensitivity. In line with this, of 56 inherited X-
linked inherited variants that have been reported in DECIPHER
and rated pathogenic or likely pathogenic by clinicians, 52 (93%)
had MPC > 1 and 38 (68%) had MPC > 2, whereas the PPVs for
variants with these filters were 31% and 53% respectively. These
results indicate the value of this population-based burden analysis
for informing improvements in clinical practice.
Contribution of de novo versus inherited variants in X-linked
recessive genes in males. In 1935, Haldane showed that the
relative contribution of de novo versus inherited variants in X-
linked recessive genes is a function of the reproductive fitness of a
disorder and the mutation rate in the paternal and maternal
germline23. Specifically, the fraction of male X-linked recessive
cases due to DNMs should be mμ
2μþν, where m is the reproductive
loss in affected males, μ is the mutation rate in eggs and ν is the
mutation rate in sperm. For DDs which are reproductively lethal
(i.e. m= 1), if the maternal and paternal germline mutations rates
were equal, one-third of pathogenic variants would be expected to
be de novo. However, the paternal mutation rate of single
nucleotide variants (SNVs), the predominant class of pathogenic
variant, is ~3.5 times higher than the maternal rate24, which
would be expected to lower the proportion of pathogenic SNVs
that arise de novo to ~18% (see ‘Methods’).
We tested Haldane’s theory by evaluating the fraction of the
estimated SNV burden (observed-expected) in X-linked recessive
genes in males that was de novo. We found that this fraction was
~36%, although, even within this large dataset, the bootstrap
confidence intervals around this estimate remain large
([19–83%]) (Supplementary Fig. 2D). Using an approximation
to a binomial distribution, we estimate that the probability of
observing our data under the null hypothesis of Haldane’s theory
is about 0.0001 (two-sided p-value from a two-sample test for
equality of proportions). Together with our results from
bootstrapping, this suggests that our data are unlikely to be
consistent with Haldane’s theory. There are at least three non-
mutually exclusive explanations for this. Firstly, the DDD study
may be biased away from classic inherited X-linked families
because these are easier to diagnose through the usual clinical
means and because patients who had been previously recruited to
the UK-wide GOLD study focused on X-linked ID1 tended not to
be recruited to DDD. Secondly, it may be that our assumption
about the ratio of male to female mutation rates differs on the X
chromosome compared to the autosomes; however, the male:
female mutation rate ratio would have to be substantially lower
on the X chromosome than the autosomes to be consistent with
the observed 36% DNMs, which seems unlikely. Finally,
Haldane’s theory did not incorporate the possibility of a reduced
number of offspring in heterozygous carrier females, which would
be expected to increase the proportion of DNMs in XLR genes.
We note that this need not be due to any physiological phenotype
in carrier females, and could include the effect of women
choosing not to have more children after having one or more
affected sons. This phenomenon is well recognised in current
clinical practice and can result in halving the number of offspring
of women known to be at risk of being carriers25.
We tested the effect of rare PTVs in XLR genes in females in
UK BioBank (N= 13 carriers; Supplementary Table 2) and found
that carrier females had a nominally significant reduced number
of children (average uncorrected values: 1.31 for carriers, 1.76 for
non-carriers; ratio t-test p= 0.038), with a fertility ratio of
carriers to noncarriers of 0.742 [0.503–0.981] (Supplementary
Fig. 4). Shermer et al.26 built on Haldane’s theory and determined
that the expected fraction of male diagnoses in XLR genes that are
de novo should be
μð2fþmmf Þ
2μþννf , where f is the reproductive loss in
female carriers, m the reproductive loss in affected males
(assumed to be 100% here), μ is the mutation rate in eggs and
ν in the mutation rate in sperm (assumed to be equal to 3.5 μ
here). Thus, the level of reduced fertility observed in female
carriers in UK Biobank implies we should expect 27.3% of the
burden in X-linked recessive genes to be de novo, and this
fraction could be as high as 39.8% considering the lower bound of
the fertility ratio. This fraction overlaps the 95% confidence
interval we estimate from bootstrapping ([19–83%]; Supplemen-
tary Fig. 2D). Hence, reduced numbers of offspring in female
carriers may be contributing to this fraction being higher than
expected under Haldane’s theory.
Gene discovery and delineation of inheritance mechanisms.
Our previous efforts at gene discovery on the X chromosome
involved testing for de novo enrichment in males and females
combined12. This is best powered to detect XLD genes but ignores
the substantial contribution from inherited variants in males, so
will be underpowered to find new XLR genes. In contrast, many
previous gene discovery studies focused on males from obviously
X-linked pedigrees so will have missed de novo causes of X-linked
disorders1. Hence, we implemented three different tests to opti-
mise power to detect XLR, XLD, and X-linked semi-dominant
(male lethal) genes (see Methods). This identified 23 genes that
passed Bonferroni correction (Supplementary Data 3). These
genes were all already known to be DD-associated, reflecting the
fact that, in our burden analysis, 78% of the excess was in these
known genes, meaning that only an additional ~1.4% of DDD
probands (~157 probands) have a diagnostic variant in an X-
linked gene not currently associated with DDs. Of these 23 genes,
19 passed Bonferroni correction in the combined analysis of both
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sexes (our old method), one (STAG2) was only significant in the
female-only test, and three were only significant when incor-
porating both de novo and inherited variants in males using the
transmission and de novo association test (TADA)27.
We observed that a subset of genes were significantly enriched
for DNMs in females only (e.g. HDAC8, NAA10, PDHA1,
SMC1A, CDKL5, STAG2), a subset only in males (UPF3B,
KDM5C), and some in both sexes (IQSEC2, CASK, WDR45) (Fig.
2a). The patterns of enrichment we observed were largely
consistent with the inheritance modes previously reported for
these genes, with the exception of MED12 which we discuss
below. In principle, this kind of large-scale data analysis should
allow us to explore modes of X-linked inheritance in a less biased
way than previous small-scale case reports in the literature. We
can see from burden analysis (Fig. 2b; positive predictive values
shown in Supplementary Fig. 5) that genes annotated as XLD
versus XLR clearly have different patterns of DNM enrichment,
indicating that there is meaningful heterogeneity among X-linked
genes. However, the fact that we still see enrichment of DNMs in
nominally XLR genes in females indicates that these classifica-
tions in the literature are not perfect.
MED12 presents a good illustration of the challenges in trying
to classify inheritance modes for X-linked genes. It had been
previously reported to cause X-linked recessive FG, Lujan and
Ohdo syndromes as well as non-syndromic intellectual disabil-
ity28–30, and DDG2P and OMIM class it as XLR. However,
heterozygous females have previously been reported with mild
and, in some cases, severe phenotypes, with the severity not
obviously being correlated with the degree of skewed X-
inactivation31–34. We observed eight damaging DNMs in females
and one in a male. The phenotypes of our patients and those
reported for other MED12 patients in the literature are largely
consistent. For five of the eight female MED12 patients, the
clinician reported that the contribution of the MED12 mutation
was ‘uncertain’, presumably partly because it is reported to be
recessive in OMIM. Our results suggest that MED12 should likely
be reclassified as causing both X-linked dominant and X-linked















































































































































Fig. 2 Sex-specific de novo burden analysis. a Burden of damaging de novo mutations (DNMs) (protein truncating variants (PTVs)+missense/inframe)
in females versus males, per gene. Shown are the 23 X-linked genes that passed multiple-testing correction. The text colour indicates whether the gene
was classed in the consensus of genes from the Developmental Disorders Gene-to-Phenotype list (DDG2P) and Online Mendelian Inheritance in Man
(OMIM) (see ‘Methods’) as X-linked dominant only (orange), X-linked recessive only (green) or both/uncertain (blue). P-values for the genes under
different tests are shown in Supplementary Data 3. b Burden of damaging (PTV+missense/inframe) DNMs for males and females in the indicated gene
sets. p: p-value from upper-tailed Poisson test. fatt: attributable fraction for DNMs in this gene set. The colored bars show the point estimates and error bars
show 95% confidence intervals calculated as described in the ‘Methods’.
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related disorders rather than distinct syndromes. Further work on
the functional consequences of different MED12 mutations and
the degree of X-inactivation in female brain tissue would be
required to understand why some mutations appear to be
recessive and others dominant.
The MED12 example above illustrates the power of these kinds
of large-scale data analyses to identify patterns of sex-biased
DNMs that are inconsistent with current classification of
inheritance mode, but ideally we would like to be able to assign
all genes to modes of inheritance with high confidence. Genes
that exhibit a substantial female bias in observed DNMs (Fig. 2b)
could be semi-dominant and lethal in males, or dominant (cause
equivalent disease in males and heterozygous females). The low
mutability of the maternally transmitted X chromosome in males
results in a low expected number of DNMs in genes pathogenic in
males. It may well be that we simply have not observed any males
with DNMs in those genes by chance due to limited sample size.
To distinguish these possibilities, we need to model the expected
number of DNMs in females versus males, given the null
mutation model, coverage, ploidy and sample size (see ‘Meth-
ods’). Under this model we would expect ~78% of DNMs on the
X chromosome to occur in females, although they only make up
43% of the trios used for the DNM enrichment tests. When we
accounted for this, we identified two genes with a nominally
significant female bias (Supplementary Table 3), MECP2
(binomial p= 0.02; 24/25= 96% of DNMs observed in females)
and DDX3X (binomial p= 0.002; 48/50= 96% of DNMs
observed in females). This provides statistical evidence that both
of these genes exhibit a semi-dominant mode of inheritance.
These two genes were recently reported to show significant female
bias for DNMs35, although that work did not correct for the
different mutation rates in males and females and hence
overestimated the significance of the female bias. MECP2 is
already known to cause female-limited Rett syndrome, and males
with verified PTV mutations have not been observed, although
missense mutations have been reported in males with severe
epileptic encephalopathy. In line with this, in both MECP2 and
DDX3X, the only DNMs in males in our cohort were missense or
inframe. MECP2 and DDX3X are among the genes with the most
DNMs in our cohort, and therefore have the most power for
assigning inheritance mode. Confident assignment of all X-linked
genes to one or other inheritance mode would require a larger
sample size than is available in this study.
Role of polygenic background. Clinicians recruiting patients to
the DDD study were asked to indicate at recruitment whether
they suspected the patient may have an X-linked cause. Male
patients with suspected X-linked inheritance (N= 271) were
enriched 2.7-fold for higher inherited X-linked coding burden
(attributable fraction= 16.4% [6.4–27.4%] versus 6.1%
[3.6–8.6%] for all males) (binomial p= 2 × 10−9). Based on
recent work showing that common variants also contribute to risk
of rare developmental disorders36, we hypothesised that polygenic
background could be contributing to the presence of multiple
affected males in families, leading clinicians to incorrectly suspect
X-linked inheritance. Using imputed genotype chip data on a
subset of the cohort, we tested for a difference in polygenic scores
for relevant traits between 216 males suspected to have X-linked
inheritance versus 3439 who were not, having excluded those
with a potentially diagnostic X-linked variant. Specifically, we
assessed polygenic scores for educational attainment37, intelli-
gence38, schizophrenia39, and severe neurodevelopmental dis-
orders (NDD) derived from our own GWAS36. None were
significantly different after correcting for four tests (linear
regression correcting for 10 genetic principal components; p >
0.05/4; Supplementary Table 4). This analysis will require more
powerful polygenic scores and a larger sample size to clarify the
contribution of polygenic background to the clustering of affected
individuals in families.
Discussion
Here we analysed the burden of de novo and inherited rare coding
variants on the X chromosome and estimated that these explain
~6% of both male and female probands in 11,044 families in the
DDD study. We found that about three-quarters of this burden
was in known DD genes. These proportions are similar to findings
in other exome-sequencing studies of similar cohorts40–42. For
example, in one of the largest comparable studies, 34/938 (3.6%
[2.5–5.0%]) male probands and 29/728 (4.0% [2.7–5.7%]) female
probands with neurological disorders had a diagnostic X-linked
variant42, versus 3.8% and 5.4%, respectively in DDD (inferred
from burden analysis in known DD-associated genes). Impor-
tantly, our results show that, when rare monogenic causes in as-
yet-undiscoveredX-linked genes are also accounted for, they still
cannot explain the male bias within our cohort. There is a com-
mon perception amongst clinicians that X-linked causes of DDs
are much less likely in females than males (except for e.g. Rett
Syndrome due to MECP2 mutations)43, but our burden analyses
do not support this. Our results imply that the discovery of the
remaining X-linked DD genes may allow us to diagnose another
~1.4% of our cohort. In contrast, we recently estimated that dis-
covery of the remaining autosomal dominant DD genes would
allow us to diagnose about another ~23% of the cohort with
pathogenic DNMs44. This likely reflects the fact that it was easier
to find X-linked DD genes than autosomal dominant DD genes in
the linkage era.
We found that ~41% of the burden on the X chromosome in
trio males was de novo, and this fraction was ~36% in XLR genes,
higher than the ~18% expected under Haldane’s theory. To our
knowledge, this number has previously only been estimated for
individual genes, and only based on likely diagnostic variants
rather than in an unbiased burden analysis (e.g. refs. 45,46). It is
important to emphasise that the fractions we have estimated in
DDD are likely higher than they would be in an unbiased sample
of DD patients. DDD may be biased away from inherited X-
linked causes due to our ascertainment strategy, which excluded
patients who already had a genetic diagnosis. X-linked inherited
causes may be easier to diagnose, since an X-linked inheritance
pattern in a family reduces the search space. Additionally, the
earlier GOLD study had already recruited several hundred of
these families in the UK, so they may have been under-recruited
to DDD. Reduced reproduction in heterozygous carrier females
might also be contributing to the higher-than-expected con-
tribution of DNMs in X-linked recessive genes; this could include
increased pre-reproductive mortality in females with skewed X-
inactivation as well as phenotypically normal mothers choosing
not to have more children after having an affected son. We
observed ~26% lower reproductive success (fertility ratio 0.742
[0.503–0.981]) in a small sample (N= 13) of carrier females in
UK Biobank compared to non-carriers, but given the large con-
fidence interval, this result should be treated with caution. Larger
sizes of relatively unbiased population samples are needed to
confirm this apparently decreased reproductive success, and to
quantify its influence on the ratio of de novo to inherited
pathogenic variants in XLR genes.
Our results have important diagnostic implications. We
demonstrated that, while the vast majority of observed de novo
and inherited PTVs in males in known X-linked DD genes are
pathogenic, inherited missense variants in these genes have only a
low PPV (Fig. 1c; Supplementary Fig. 4). This implies that it is
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challenging to accurately diagnose males with rare inherited
missense variants in X-linked DD genes, particularly since the
high recurrence risk for such variants presents a legitimate con-
cern and thus may increase motivation for clinicians to take
action. Additional simple manoeuvres such as testing the
apparently unaffected males in the family for an inherited mis-
sense variant identified in an index male can be very helpful in
excluding causality but are rarely deployed outside of clinical
genetics services. On the other hand, our comparison with
ClinVar (Fig. 1b) suggests that, in fact, current clinical inter-
pretation is likely highly conservative and missing a large fraction
of pathogenic missense variants in X-linked DD genes in males,
since PTVs are relatively enriched in the ClinVar likely patho-
genic/pathogenic variants compared to our burden analysis.
Indeed, assuming that all diagnostic PTVs are being identified, we
estimate from this analysis that ~58% of diagnostic missense/
inframe variants in known X-linked DDG2P genes are not being
classed as pathogenic. Incorporating CADD and MPC scores
during variant interpretation may improve specificity in clinical
diagnosis, but reduce sensitivity (Fig. 1c). For example, con-
sidering all inherited missense variants absent from gnomAD in
DDG2P genes, 13% [4–22%] of these will be truly pathogenic,
versus 53% [37–65%] of those with MPC score > 2, but applying
the latter filter may lose about a third of diagnoses.
We developed an improved strategy for finding X-linked
Mendelian disease genes that considers several different inheri-
tance modes and incorporates both de novo and inherited var-
iation in males, incorporating and building on the TADA
method27. We showed that this strategy identified 21% (23 versus
19) more X-linked DD-associated genes at genome-wide sig-
nificance than our previous approach. However, all genes that
passed genome-wide significance were already known, reflecting
low power which is due to the fact that only ~1.4% of the cohort
has an X-linked diagnosis in an as-yet-undiscovered gene.
Although our approach was designed to distinguish XLD from
XLR genes, it is clear that more data will be needed from larger
cohorts for a data-based classification of inheritance modes.
Furthermore, information in X-inactivation in females may help
us to interpret inheritance modes, since this does contribute to
penetrance in females, although accessibility of the relevant tissue
is likely to be a challenge here. Larger sample sizes may reveal
more X-linked genes with a sex bias other than just DDX3X and
MECP235 which appear to be semi-dominant; we emphasise that,
in testing for these, it will be important to account for the dif-
ferential rates of DNMs on the X chromosome in the two sexes,
otherwise the degree of female bias will be over-estimated (see
‘Methods’).
Our study has several limitations. Firstly, there are wide con-
fidence intervals around several of the key parameters we have
estimated (attributable fraction, fraction of de novo versus
inherited causes, positive predictive value, etc.), despite our
relatively large sample size. An even larger sample size would
increase the precision of these estimates. Secondly, there may be
ascertainment bias in the DDD study away from very recogni-
sable disorders and families with a clear XLR inheritance pattern.
This means our estimates of important parameters will not
necessarily hold for other cohorts. Large cohorts in which exome-
sequencing has been applied as a first-line test will allow less
biased estimates. Finally, our attempts at new gene discovery and
classification of inheritance modes were limited not only by
sample size, but also by lack of data on X-inactivation in females
and the phenotypes of carrier mothers. Furthermore, we antici-
pate that extra data will reinforce that many X-linked genes can
show both dominant and recessive inheritance depending on the
severity of the variant, including, for some genes, different phe-
notypic features associated with hemizygous versus heterozygous
variants (e.g. NAA1047). Hence, future gene discovery efforts will
need to develop unbiased ways of discriminating between dif-
ferent disorders caused by mutations in the same gene on the
basis of phenotype or functional evidence.
It is notable that within our cohort, less than a quarter of males
who were suspected by clinicians to have an X-linked condition
were inferred to have a pathogenic rare or de novo X-linked
coding variant in any gene. This may imply that there are other
factors contributing to the recurrence of a DD in multiple males
from the same family. Under the hypothesis that males have a
lower liability threshold than females for NDDs, it seems plau-
sible that an enrichment of multiple deleterious variants across
the frequency spectrum might push multiple males but not
females in a family over this threshold, creating the appearance of
X-linked Mendelian inheritance. We did not see a difference in
polygenic scores (with MAF > 5% variants) for relevant traits
between males without likely diagnostic X-linked variants who
were suspected to have an X-linked disorder versus those who
were not. However, given that existing polygenic scores for
intelligence explain only ~4–5% of variance in IQ in out-of-
sample prediction48–50, we anticipate that we may see a difference
with a larger sample size and more informative polygenic scores,
potentially including rarer variants that have been shown to
explain a substantial proportion of variance in intelligence51.
In conclusion, our work shows that monogenic causes on the X
chromosome cannot account for the male bias in developmental
disorders. Analyses of variants across the full frequency spectrum
in large cohorts may reveal a contribution of more common
variants to the sex bias. This work provides a robust statistical
framework for analyses of the X chromosome in large Mendelian
disease cohorts, which will aid in future gene discovery and
inform improvements in clinical practice.
Methods
Family recruitment. Individuals with severe, undiagnosed developmental dis-
orders were recruited to the DDD project by 24 clinical genetics centres within the
United Kingdom National Health Service and the Republic of Ireland. They had to
have at least one of the following phenotypes:
1. Neurodevelopmental disorder—for example, developmental delay and/or
learning disability (of a level requiring or likely to require a statement of special
educational needs), epileptic encephalopathy or cerebral palsy.
2. Congenital anomalies—multiple congenital anomalies (two or more major
anomalies) or a single major anomaly together with a neurodevelopmental
disorder, aberrant growth, dysmorphic features or unusual behaviour.
3. Abnormal growth parameters (height, weight, head circumference (OFC))—
two or more parameters >3 SD above or below the mean or a single parameter >4
SD above or below the mean (except for obesity where the threshold for isolated
obesity is >4.5 SD together with a strong suspicion of a genetic aetiology).
4. Unusual behavioural phenotype in conjunction with one or more of the
above features or extreme behavioural phenotype strongly suspected to have a
genetic basis (including classical autism).
5. Genetic disorder of significant impact for which the molecular basis is
currently unknown with: (i) several affected family members or (ii) one other
affected family member with a rare, consistent and distinctive phenotype or (iii) a
single case that is associated with a severe phenotype.
Families gave informed consent to participate, and the study was approved by
the UK Research Ethics Committee (10/H0305/83, granted by the Cambridge
South Research Ethics Committee and GEN/284/12, granted by the Republic of
Ireland Research Ethics Committee). DNA was collected from saliva samples
obtained from the probands and their parents, and from blood obtained from the
probands. The individuals analysed in this paper include those analysed in the
previous publications12,44,52,54,55.
Clinical features. The patients were systematically phenotyped using Human
Phenotype Ontology (HPO) terms56, and growth measurements, developmental
milestones, family history (including whether X-linked inheritance was suspected)
etc. were collected within DECIPHER57. For the summary of phenotypes and
comparison between the sexes (Supplementary Fig. 1, Supplementary Data 1), we
followed the procedure in ref. 55 when counting organ systems affected, to avoid
double-counting HPO terms that fall under multiple organ systems. For the
comparison of age at walking and talking in Supplementary Table 1, we excluded
probands who had not yet reached these milestones; the sample sizes are shown in
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the table. We used linear regression correcting for age at assessment to compare
quantitative phenotypes between sexes, and logistic regression correcting for age at
assessment to compare the frequency of binary phenotypes between sexes.
Exome sequencing, variant annotation and variant quality control. We carried
out Illumina exome sequencing using the Agilent v3 or v5 baits12. Mapping of
short-read sequences for each sequencing lanelet was carried out using the
Burrows-Wheeler Aligner using both the aln algorithm (BWA version 0.5.10) and
the bwa-mem algorithm (BWA version 0.7.12), with the GRCh37 1000 Genomes
Project phase 2 reference (also known as hs37d5). Sample-level BAM improvement
was carried out using the Picard Markduplicates (versions 1.98 and 1.114) and
Genome Analysis Toolkit IndelRealigner (GATK version 3.1.1 and version 3.5.0),
which performs realignment of reads around known and discovered indels
(insertions and deletions). Single-nucleotide variants (SNVs) and indels were called
using the GATK HaplotypeCaller, CombineGVCFs and GenotypeGVCFs (GATK
version 3.5.0). Bcftools (version 1.8-30-gb717d08) and custom Perl (version 5)
scripts were used to filter the variants for the case/control analysis.
Variants were annotated with Ensembl Variant Effect Predictor58 based on
Ensembl gene build 88, using the LOFTEE plugin. We analysed three categories of
variant based on the predicted consequence: (1) protein-truncating variants (PTVs)
classed as ‘high confidence’ loss-of-function variants by LOFTEE (including the
annotations splice donor, splice acceptor, stop gained, frameshift, initiator codon
and conserved exon terminus variant); (2) missense variants and inframe indels;
(3) synonymous variants. We assigned each variant the worst consequence across
all the transcripts for a gene. Missense variants were annotated with CADD v1.321
and MPC22 scores. All variants were annotated with MAF data from four different
populations of the 1000 Genomes Project59 (American, Asian, African and
European), two populations from the NHLBI GO Exome Sequencing Project
(European Americans and African Americans) and six populations from the
Genome Aggregation Consortium (gnomAD) release 2.0.2 (African, East Asian,
non-Finnish European, Finnish, South Asian, Latino,), and internal allele
frequencies from the European and South Asian unaffected DDD parents.
For the case-control analysis of chrX in males, we used the following filters:
● Genotypes were set to missing if they had genotype quality (GQ) < 20, depth
(DP) < 7, or were called as heterozygous.
● Variants were removed if they met any of the following criteria:
■ were in the pseudoautosomal regions (chrX:60001-2699520 and
chrX:154931044-155260560 in GCh37)
■ had a strand bias p-value < 0.001
■ had >50% missing calls (after the genotype-level filtering) within the
samples that underwent Agilent SureSelect Human All Exon V5 capture
or within those that underwent Agilent SureSelect Human All Exon V3
capture
■ had minor allele frequency (MAF) > 0.001 in any gnomAD population or
in the unaffected European or South Asian parents from DDD. For
calculating the PPV for lower MAF variants (MAF < 0.0005, 0.0001,
0.00005), we only considered the gnomAD POPMAX and the frequency
in European DDD parents, since the set of South Asian DDD parents in
DDD was too small.
■ had any hemizygotes in gnomAD
For calling DNMs on chrX, we ran DeNovoGear12,60, but with a different set of
hard filters to account for the lower coverage in males and to maximise sensitivity
and specificity. We examined all candidate DNMs in males and a large subset of
those in females manually in IGV, and used this to settle on the following set of
filters:
● We removed DNMs in the pseudoautosomal regions.
● The variant had to be called heterozygous or (for males) hemizygous in the
child in the original GATK calls, and called homozygous reference in the
parents.
● For male probands, we required the following: in the child, alternate allele
depth >2 and overall depth > 2; in the mother, depth >5.
● For female probands, we required the following: in the child, alternate allele
depth >2, overall depth >7; in the mother, depth >5; in the father, depth >1.
● For single nucleotide variants, we required p > 10−3 on a Fisher’s exact test for
strand bias, pooling across trios (or mother-child pairs, for male probands)
where a DNM was called at the same site by DeNovoGear.
● For female probands, we removed indels <5 bp if they had variant allele
fraction <0.3 or MAF > 0, since these were vastly over-represented and seemed
to be a common error mode.
● We did a two-sided binomial test on the number of alternate reads at the
candidate site in mothers, assuming the proportion of these should be 0.5 if
heterozygous, and then discarded sites where the p-value from this test (called
phet) was >0.01, since these indicated that the mother was likely to be truly
heterozygous and not mosaic.
● We did a binomial test to evaluate whether the fraction of alternate reads was
greater than the expected error rate of 0.2% (perror), and then flagged variants
as mosaic if they had lower-tailed phet < 0.01 and upper-tailed perror < 0.01.
We then removed variants in segmental duplications if both the child and at
least one parent (mother for female probands) were flagged as mosaic.
● We set a cutoff for the posterior probability of being a DNM from
DeNovoGear to ppDNM > 0.00247679. This value was chosen because the
observed number of synonymous DNMs in females that passed this ppDNM
cutoff, as well as the hard filters above, was very close to the expected number.
calculated using null mutation rate determined as described below. We chose
to calibrate the ppDNM threshold in females since the numbers in males were
very small.
We subsequently removed DNMs that had MAF > 0.001 in any gnomAD
population or in the unaffected European or South Asian parents from DDD, or
that had any hemizygotes in gnomAD.
Calculation of expected mutation rates on chrX. We estimated the expected
number of DNMs per gene in different functional classes using the method in
ref. 10. We adjusted for the reduced sensitivity to detect DNMs due to limited
coverage following the method in ref. 61, with some minor adaptations. For this, we
first calculated the median depth per exon in 250 samples on the Agilent V5
capture, and then took the mean of these. To determine the depth-uncorrected
expected number of variants per exon, we took the exons with mean median depth
≥30 and regressed the number of rare (MAF < 0.001) synonymous variants on the
probability of a synonymous mutation. For males and females separately, we
plotted the ratio of observed to depth-uncorrected expected synonymous variants
against the depth in bins of 2× (for up to 40× in males and 80× in females) and
fitted a logarithmic curve. We then used this formula to predict the depth-corrected
expected number of variants for all exons:
depth-adjusted expected count ¼
0 if depth< 1
expected count ´ 0:2778 ln depthð Þ þ 0:0279ð Þ if 1< depth< 30 inmales
expected count ´ 0:2464 ln depthð Þ þ 0:035ð Þ if 1< depth< 50 in females









In calculating the expected counts of DNMs in the non-pseudoautosomal
regions of chrX in males and females, we followed the method previously described
in53 to account for the different inheritance pattern of this chromosome and the
different mutation rates in the male and female germline. Specifically, we
determined the scaling factors as follows:
ffemales ¼ tF>F þ tM>F ¼ nfemaleλfemale þ nfemaleλmale ð2Þ
fmales ¼ tF>M ¼ nmaleλfemale ð3Þ
where tF>F and tM>F are the number of transmissions from females and males to
female probands respectively, tF>M is the number of transmissions from females to
male probands, nfemale and nmale are the numbers of female and male probands, and










where α= 3.4 is the ratio of the mutation rate in fathers to mothers in DDD,
determined using 199 phased DNMs53. These scaling factors ffemales and fmales were
multiplied by the depth-adjusted mutation rates to determine the expected number
of DNMs as nfemaleμfemale and nmaleμmale.
Sample quality control. We removed probands with sex chromosome aneu-
ploidies (N= 47) or whose chromosomal sex did not match the sex recorded by the
clinician (N= 49). We also removed six probands with an implausibly high
number of de novo calls, likely to be spurious, and 330 samples with >20% missing
genotypes on chrX after the genotype QC described above. We used KING62 to
estimate relatedness between individuals, applying it to variants with MAF > 0.01
with <5% missingness after genotype QC. Then, for unaffected fathers (who were
used as controls) and for probands separately, we removed one person from each
pair of individuals inferred to be third-degree relatives or closer (doing this in such
a way as to minimise the number of individuals removed); this led to the removal
of 586 male probands, 211 female probands and 108 unaffected fathers. In total,
1311 unique individuals were removed. The final analysis after QC was conducted
on 7136 male probands (5138 in trios), 3908 female probands in trios, and 8551
unaffected fathers.
Burden analysis. We conducted sex-specific burden analyses to test for an
enrichment of certain classes of X-linked variants in probands and to estimate the
fraction of probands attributable to such variants.
1. In males, we conducted a case/control analysis comparing male probands to
the unaffected fathers. This incorporates both maternally inherited variants
and DNMs that passed the genotype and variant filtering for the case/
control analysis (but did not necessarily pass the filtering of mutations called
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by DeNovoGear). In the case-control analysis, we calculated the rate of a
particular class of variant per person in the unaffected fathers and used this
to calculate the expected number of variants in the male probands by simply
multiplying this rate by the number of probands.
2. In both females and males, we conducted a DNMs enrichment analysis
comparing the observed number of DNMs to the expected number, as
calculated above.
For both burden analyses, we restricted to variants with maximum MAF< 0.001
and with no hemizygotes in gnomAD, to try to restrict to the most damaging subset of
variants. We also examined synonymous, PTV and missense/inframe variants (the
latter filtered in various ways) separately. Synonymous variants were used as a control:
we confirmed that the number of observed synonymous variants was not significantly
different from expectation, to ensure that the test was well-calibrated.
We tested for enrichment assuming a Poisson distribution using an upper-tailed


















For DNMs, we treated the observed number as a fixed quantity, calculated 95%
confidence intervals on the number of expected DNMs using the poisson.test()
function in R, and then substituted these into the above formulae to calculate
confidence intervals on those metrics. For the case/control analysis in males, the
expected rate of variants is calculated based on the number observed in fathers, so
is a random variable. Thus, we used the moverci() function in R to calculate
confidence intervals on the difference or ratio of two Poisson rates, and substituted
these back into the above formula as appropriate. Specifically, the confidence
interval for each metric was calculated as follows:
● burden: moverci (Vprobands, Nprobands, Vfathers, Nfathers,distrib= ‘poi’, contrast
= ‘RR’) (i.e. a rate ratio) where N is the number of individuals and V is the
number of observed variants.
● attributable fraction: moverci (Vprobands, Nprobands, Vfathers, Nfathers, distrib
= ‘poi’, contrast= ‘RD’) (i.e. a difference in rates)
● PPV: 1-moverci (Vfathers, Nfathers, Vprobands, Nprobands, distrib= ‘poi’, contrast
= ‘RR’)
To calculate a confidence interval on the fraction of pathogenic variants that
were in known genes and the fraction of pathogenic variants in XLR genes in male
trio probands that was de novo, we bootstrapped probands. Specifically:
● For females, we bootstrapped probands 1000 times, each time recalculating the
excess number (excess ¼ #observed #expected) of DNMs in all genes and




across the 1000 iterations (Supplementary Fig. 2B).
● For males, we bootstrapped probands and fathers each separately 1000 times,
each time recalculating the excess number of variants in probands in all genes
and in known X-linked DD genes, then determined the 2.5th and 97.5th
percentile of the ratio
excessvars;known genes
excessvars;all genes
across the 1000 iterations (Supplementary
Fig. 2A). We repeated this procedure with just the male trio probands, and
used the same 1000 sets of bootstrapped trios to also calculate excessvars;all genes ,
excessvars;XLR genes , excessDNM;all genes and excessDNM;XLR genes , then determined the
5th and 95th percentile of the ratios
excessDNM;all genes
excessvars;all genes
(Supplementary Fig. 2C) and
excessDNM;known genes
excessvars;known genes
(Supplementary Fig. 2D). In Supplementary Fig. 2DA, C, the
97.5th percentile of the ratio was greater than 1, so in the text we report the
upper bound of those confidence intervals to be 100%.
Per-gene enrichment tests. For each gene, we tested for a significant burden of
DNMs using a Poisson test, calculating the expected number of DNMs using the
expected mutation rate obtained as described above53. For males and females combined
(the old test) and for females alone, we tested PTVs alone and PTVs and missense/
inframe variants combined, then took the lowest p-value for each proband set.
We also applied the transmission and de novo association test (TADA)27 to each
gene in males to test for enrichment of de novo and inherited variants combined. The
inherited counts were determined from the male probands and their fathers,
respectively. We removed from these counts the de novos that passed our
DeNovoGear filtering, since these were counted already in the TADA de novo
mutation model; we also tried removing from the inherited counts variants that did
not pass the DeNovoGear filtering but which had 0 alternate reads in mothers, and
counting these as DNMs, but in practice this made little difference to the results. Since
there are ~15% of genes on chrX already implicated in DDs (in the DDG2P list) but it
was unclear how the case ascertainment in DDD might have created biases against
these, we tried varying π, the prior on the fraction of risk genes, from 0.05 to 0.25.
Other prior parameters were calculated accordingly, following the procedure described
in the TADA user guide (http://www.compgen.pitt.edu/TADA/TADA_guide.html).
These are shown in Supplementary Table 5. For all runs, as parameters in the prior for
the allele frequencies, we set υ= 100 and ρ= 0.618 for PTVs, and υ= 100 and ρ=
11.749 for missense/inframe variants. We ran TADA separately on PTVs alone and on
PTVs and missense/inframe variants combined.
We calculated q-values using the Bayesian.FDR() function in TADA, and p-
values using a sampling approach via the TADAnull() and bayesFactor.pvalue()
functions.
Under the old testing strategy (PTVs alone and PTVs+missense/inframe
variants combined for males and females combined), we corrected for 2 × 19,685
genes, giving a genome-wide significance threshold of p < 0.05/2 × 19,685=1.27 ×
10−6. Under our improved testing strategy, overall we applied six tests to each of
804 X-linked genes: (A) PTVs alone and (B) PTVs+missense/inframe variants
combined for each of (1) DNMs in females alone (Poisson), (2) DNMs in males
and females combined (Poisson), and (3) DNMs and inherited variants in males
(TADA). Since we would typically apply two separate DNM enrichment tests to
each autosomal gene (PTVs alone and PTVs+missense/inframe variants), in total,
we corrected for (6 × 804+ 2 × (19,685− 804)) tests, giving a genome-wide
significance threshold of p < 0.05/40780= 1.17 × 10−6.
Testing for sex bias in DNMs per gene. For each gene, we calculated the fraction
of expected PTV+missense/inframe DNMs that should be in males as:
expected fraction of DNMs inmales ¼
nmaleμmale=ðnmaleμmale þ nfemaleμfemaleÞ
ð8Þ
We used the mutation rates calculated as described above accounting for
coverage and ploidy. We then compared the fraction of observed DNMs that were
in males to this expected fraction using a lower-tailed binomial test (under the
hypothesis that the gene would be depleted for DNMs in males due to lethality).
Gene list definitions. To define the list of known X-linked DDG2P genes, we took
the intersection of confirmed or probable DDG2P genes on the X chromosome and
OMIM genes with a disease annotation. To define ‘X-linked recessive’ (called
‘hemizygous’ in DDG2P) and ‘X-linked dominant’ genes, we compared the
inheritance annotations between DDG2P and OMIM and took the consensus.
Hence, ‘X-linked recessive’ genes were those annotated only as hemizygous in
DDG2P and only as X-linked recessive in OMIM, and similarly for X-linked
dominant genes. There were 12 genes classified as exclusively X-linked dominant
and 63 as exclusively X-linked recessive. Genes annotated as both X-linked
dominant and X-linked recessive, or annotated simply as ‘X-linked’ in either
DDG2P and OMIM, have been coloured in blue in Fig. 2, and excluded from
analysis of X-linked recessive genes and from Supplementary Figs. 2D, 4 and 5.
Investigating the de novo versus inherited contribution in X-linked recessive
genes. Under Haldane’s theory, the fraction of male X-linked recessive cases due to





where m is the reproductive loss in affected males, μ is the mutation rate in eggs
and ν in the mutation rate in sperm. If we assume m= 1 and that ν= 3.5μ (based
on a previous estimate24), we should expect pde novo to be about
1
5:5 ’18.2%.
We focused on X-linked recessive genes from DDG2P that were not also
annotated as X-linked dominant, and included only PTV and missense SNVs
because the male to female mutation rate ratio was calculated for SNVs. We
estimated (based on the excess=observed-expected) that 68.5 [31.2–102.9] male
trio cases could be attributed to pathogenic variants in these genes, of which 21.8
[15.5–24.8] were de novo. Assuming the data approximate a binomial distribution,
we tested the consistency with Haldane’s theory using a two-sample test for
equality of proportions; specifically, we used prop.test(22,69, p= 1/5.5) in R. We
also assessed consistency with Haldane’s theory through bootstrapping as described
in the “Burden analysis” section above.
Sherman et al. modified Haldane’s theory to account for reduced reproductive
fitness in carrier females26. Under their theory, pde novo should be:
pde novo;Sherman ¼
μð2f þmmf Þ
2μþ ν  νf
ð10Þ
where f is the reproductive loss in carrier females. We again assume m= 1 and ν=
3.5μ. Any value of pde novo between 0.22 and 0.44 should be consistent (p-value > 0.05)
with the excess values we observed. This corresponds to a value for f between ~12%
and ~56%. We next turned to the UK Biobank exome data to estimate f directly.
UK Biobank analysis. We downloaded variant calls for all 49,959 samples sub-
jected to WES as part of the UK Biobank study63. We next annotated all variants
with Variant Effect Predictor (v97)58, extracted variants in exclusively X-linked
recessive genes, and retained only the most severe consequence in canonical
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transcripts. We note that none of these X-linked recessive genes are affected by the
recently-reported problem with this UK Biobank exome data release which is
related to mapping errors64.
We then removed PTV and missense variants with CADD ≤ 2565, missense
variants with an MPC22 score ≤2, low-confidence PTV variants using the LOFTEE
plugin for VEP66, and all variants with a gnomAD19non-Finish European
minimum allele frequency ≥0.001. Only UK Biobank variants with a UK Biobank
allele frequency ≤1 × 10−3 were retained for downstream analysis. To further
ensure that we did not include any deleterious variants of potentially incomplete
penetrance, we also filtered any PTV and missense variants which were also found
in any male individuals in UK Biobank. We then removed all related, non-white
British ancestry individuals and all males, leaving a final total of 18,632 female
samples. PTV, missense, and synonymous variants passing the above criteria were
then counted for each remaining individual (Supplementary Fig. 4A). All 13 likely
PTV variants in X-linked recessive genes we identified were confirmed via manual
inspection using the Integrative Genomics Viewer67 (Supplementary Table 4).
To determine the total number of live births for each female in UK Biobank, we
downloaded field 2734. To determine fluid intelligence scores, we downloaded field
20016. Only data obtained via in-centre testing were retained for further analysis.
Age and pre-computed ancestry PCs68 were obtained from UK Biobank fields
21022 and 22009, respectively. To independently determine the effect of PTV,
missense, or synonymous variants on each phenotype, we used a simple linear
model (via the glm function in R with family “gaussian”) in the form:
phenotype  NVAR þ ageþ age
2 þ PC1þ::::þPC10 ð11Þ
where phenotype is either number of live births or normalised fluid intelligence,
and NVAR is one of total PTV, missense, or synonymous variants in each individual
in all confirmed X-linked recessive DD genes (Supplementary Fig. 4B, C). To
determine the ratio of number of live births between X-linked recessive PTV carrier
and non-carrier females, corrected for age and ancestry PCs, we used the function
ttestratio from the R package mratios v1.4.0 with default settings.
Polygenic score analysis. We restricted the analysis to 4168 male probands with a
neurodevelopmental disorder who had been genotyped on the CoreExome array,
had European ancestry and passed our quality control in36. We excluded 513 males
who had an X-linked variant in a DDG2P gene reported to DECIPHER that had
not yet been classed as ‘benign’ or ‘likely benign’ by clinicians (but note that many
of these variants reported in DECIPHER had not yet been evaluated by clinicians
and are likely to be deemed benign eventually). Polygenic scores for educational
attainment37, intelligence38 and schizophrenia39 were calculated using the pruning
and thresholding method (see parameters in Extended Data Table 2 of ref. 36). For
calculating the NDD polygenic score, we repeated the GWAS in the same dataset
described in ref. 36 but without sex as a covariate, then used p < 1 and r2 < 0.1 when
pruning the SNPs. For the comparisons of polygenic scores between males who
were versus were not suspected by clinicians to have an X-linked diagnosis, we ran
a linear regression of polygenic score on suspected group status plus 10 genetic
principal components.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The full variant call files used in this study are accessible in the European Genome-
Phenome Archive as dataset EGAD00001004389, and a file of phenotypic and family
descriptions under EGAD00001004388. Both of these are under managed access to
ensure that the work proposed by the researchers is allowed under the study’s ethical
approval. The de novo mutations used in the analysis are in Supplementary Data 2.
Databases used in this study: Online Mendelian Inheritance in Man https://omim.org/;
ClinVar https://www.ncbi.nlm.nih.gov/clinvar/; Developmental Disorder Gene-to-
Phenotype list https://www.ebi.ac.uk/gene2phenotype/downloads; GRCh37 1000
Genomes Project phase 2 reference (hs37d5) https://www.ncbi.nlm.nih.gov/assembly/
GCF_000001405.13/.
Code availability
Code used to implement the analysis in this paper is available at https://github.com/
hilarymartin/DDD_chrX69.
Received: 16 March 2020; Accepted: 8 December 2020;
References
1. Tarpey, P. S. et al. A systematic, large-scale resequencing screen of X-
chromosome coding exons in mental retardation. Nat. Genet. 41, 535–543
(2009).
2. Jónsson, H. et al. Parental influence on human germline de novo mutations in
1,548 trios from Iceland. Nature 549, 519–522 (2017).
3. Amos-Landgraf, J. M. et al. X Chromosome–inactivation patterns of 1,005
phenotypically unaffected females. Am. J. Hum. Genet. 79, 493–499 (2006).
4. Tukiainen, T. et al. Landscape of X chromosome inactivation across human
tissues. Nature https://doi.org/10.1101/073957 (2017).
5. Fieremans, N. et al. Identification of intellectual disability genes in female
patients with a skewed X-inactivation pattern. Human Mutation. 37, 804–811
(2016).
6. Lubs, H. A., Stevenson, R. E. & Schwartz, C. E. Fragile X and X-linked
intellectual disability: four decades of discovery. Am. J. Hum. Genet. 90,
579–590 (2012).
7. Dobyns, W. B. et al. Inheritance of most X-linked traits is not dominant or
recessive, just X-linked. Am. J. Med. Genetics. 129A, 136–143 (2004).
8. Thormann, A. et al. Flexible and scalable diagnostic filtering of genomic
variants using G2P with Ensembl VEP. Nat. Commun. 10, 2373 (2019).
9. Piton, A., Redin, C. & Mandel, J.-L. XLID-causing mutations and associated
genes challenged in light of data from large-scale human exome sequencing.
Am. J. Hum. Genet. 93, 368–383 (2013).
10. Samocha, K. E. et al. A framework for the interpretation of de novo mutation
in human disease. Nat. Genet. 46, 944–950 (2014).
11. Sifrim, A. et al. Distinct genetic architectures for syndromic and
nonsyndromic congenital heart defects identified by exome sequencing. Nat.
Genet. 48, 1060–1065 (2016).
12. Deciphering Developmental Disorders Study. Prevalence and architecture of
de novo mutations in developmental disorders. Nature 542, 433–438 (2017).
13. Singh, T. et al. The contribution of rare variants to risk of schizophrenia in
individuals with and without intellectual disability. Nat. Genet. 49, 1167–1173
(2017).
14. Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both
developmental and functional changes in the neurobiology of autism. Cell 180,
568–584 (2020). e23.
15. Piton, A. et al. Systematic resequencing of X-chromosome synaptic genes in
autism spectrum disorder and schizophrenia. Mol. Psychiatry 16, 867–880
(2011).
16. Raymond, F. L. X linked mental retardation: a clinical guide. J. Med. Genet. 43,
193–200 (2006).
17. Fombonne, E. Epidemiological surveys of autism and other pervasive
developmental disorders: an update. J. Autism Dev. Disord 33, 365–382 (2003).
18. Smith, M. E., Lecker, G., Dunlap, J. W. & Cureton, E. E. The effects of race,
sex, and environment on the age at which children walk. Pedagog. Semin. J.
Genet. Psychol. 38, 489–498 (1930).
19. Karczewski, K. J. et al. The mutational constraint spectrum quantified from
variation in 141,456 humans. Nature 581, 434–443 (2020).
20. Landrum, M. J. et al. ClinVar: improving access to variant interpretations and
supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
21. Kircher, M. et al. A general framework for estimating the relative
pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).
22. Samocha, K. E., Kosmicki, J. A. & Karczewski, K. J. Regional missense
constraint improves variant deleteriousness prediction. BioRxiv. Preprint at
https://doi.org/10.1101/148353 (2017).
23. Haldane, J. B. S. The rate of spontaneous mutation of a human gene. J. Genet.
31, 317 (1935).
24. Rahbari, R. et al. Timing, rates and spectra of human germline mutation. Nat.
Genet. 48, 126–133 (2016).
25. Turner, G. et al. Restoring reproductive confidence in families with X-linked
mental retardation by finding the causal mutation. Clin. Genet. 73, 188–190
(2008).
26. Sherman, S. L., Morton, N. E., Jacobs, P. A. & Turner, G. The marker (X)
syndrome: a cytogenetic and genetic analysis. Ann. Hum. Genet. 48, 21–37
(1984).
27. He, X. et al. Integrated model of de novo and inherited genetic variants yields
greater power to identify risk genes. PLoS Genet. 9, e1003671 (2013).
28. Vulto-van Silfhout, A. T. et al. Mutations in MED12 cause X-linked Ohdo
syndrome. Am. J. Hum. Genet. 92, 401–406 (2013).
29. Schwartz, C. E. et al. The original Lujan syndrome family has a novel missense
mutation (p.N1007S) in the MED12 gene. J. Med. Genet. 44, 472–477 (2007).
30. Risheg, H. et al. A recurrent mutation in MED12 leading to R961W causes
Opitz-Kaveggia syndrome. Nat. Genet. 39, 451–453 (2007).
31. Bouazzi, H., Lesca, G., Trujillo, C., Alwasiyah, M. K. & Munnich, A.
Nonsyndromic X-linked intellectual deficiency in three brothers with a novel
MED12 missense mutation [c.5922G>T (p.Glu1974His)]. Clin. Case Rep. 3,
604–609 (2015).
32. Lesca, G. et al. Clinical and neurocognitive characterization of a family with a
novel MED12 gene frameshift mutation. Am. J. Med. Genet. A 161A,
3063–3071 (2013).
33. Prontera, P. et al. A novel MED12 mutation: evidence for a fourth phenotype.
Am. J. Med. Genet. A 170, 2377–2382 (2016).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20852-3
10 NATURE COMMUNICATIONS |          (2021) 12:627 | https://doi.org/10.1038/s41467-020-20852-3 | www.nature.com/naturecommunications
34. Rubinato, E. et al. MED12 missense mutation in a three-generation family.
Clinical characterization of MED12-related disorders and literature review.
Eur. J. Med. Genet. 63, 103768 (2019).
35. Turner, T. N. et al. Sex-based analysis of de novo variants in
neurodevelopmental disorders. Am. J. Hum. Genet. https://doi.org/10.1016/j.
ajhg.2019.11.003 (2019).
36. Niemi, M. E. K. et al. Common genetic variants contribute to risk of rare
severe neurodevelopmental disorders. Nature 562, 268–271 (2018).
37. Lee, J. J. et al. Gene discovery and polygenic prediction from a genome-wide
association study of educational attainment in 1.1 million individuals. Nat.
Genet. 50, 1112–1121 (2018).
38. Sniekers, S. et al. Genome-wide association meta-analysis of 78,308 individuals
identifies new loci and genes influencing human intelligence. Nat. Genet. 49,
1107–1112 (2017).
39. Pardiñas, A. F. et al. Common schizophrenia alleles are enriched in mutation-
intolerant genes and in regions under strong background selection. Nat.
Genet. 50, 381–389 (2018).
40. Yamamoto, T. et al. Genomic backgrounds of Japanese patients with
undiagnosed neurodevelopmental disorders. Brain Dev 41, 776–782
(2019).
41. Fernández-Marmiesse, A. et al. Rare variants in 48 genes account for 42% of
cases of epilepsy with or without neurodevelopmental delay in 246 pediatric
patients. Front. Neurosci. 13, 1135 (2019).
42. Yang, Y. et al. Molecular findings among patients referred for clinical whole-
exome sequencing. JAMA 312, 1870–1879 (2014).
43. De Luca, C., Race, V., Keldermans, L., Bauters, M. & Van Esch, H. Challenges
in molecular diagnosis of X-linked Intellectual disability. Br. Med. Bull.
https://doi.org/10.1093/bmb/ldz039 (2020).
44. Kaplanis, J. et al. Evidence for 28 genetic disorders discovered by combining
healthcare and research data. Nature 586, 757–762 (2020).
45. Garcia, S. et al. Identification of de novo mutations of Duchénnè/Becker
muscular dystrophies in southern Spain. Int. J. Med. Sci. 11, 988–993 (2014).
46. Leslie, N. D. Haldane was right: de novo mutations in androgen insensitivity
syndrome. J. Pediatr. 132, 917–918 (1998).
47. Wu, Y. & Lyon, G. J. NAA10-related syndrome. Exp. Mol. Med. 50, 85 (2018).
48. Davies, G. et al. Study of 300,486 individuals identifies 148 independent genetic
loci influencing general cognitive function. Nat. Commun. 9, 2098 (2018).
49. Karavani, E. et al. Screening human embryos for polygenic traits has limited
utility. Cell 179, 1424–1435 (2019). e8.
50. Savage, J. E. et al. Genome-wide association meta-analysis in 269,867
individuals identifies new genetic and functional links to intelligence. Nat.
Genet. 50, 912–919 (2018).
51. Hill, W. D. et al. Genomic analysis of family data reveals additional genetic
effects on intelligence and personality. Mol. Psychiatry 23, 2347–2362 (2018).
52. Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD
study: a scalable analysis of genome-wide research data. Lancet 385,
1305–1314 (2015).
53. Deciphering Developmental Disorders Study. Large-scale discovery of novel
genetic causes of developmental disorders. Nature 519, 223–228 (2015).
54. Akawi, N. et al. Discovery of four recessive developmental disorders using
probabilistic genotype and phenotype matching among 4,125 families. Nat.
Genet. 47, 1363–1369 (2015).
55. Martin, H. C. et al. Quantifying the contribution of recessive coding variation
to developmental disorders. Science 362, 1161–1164 (2018).
56. Kohler, S. et al. Clinical diagnostics in human genetics with semantic
similarity searches in ontologies. Am. J. Hum. Genet. 85, 457–464 (2009).
57. Bragin, E. et al. DECIPHER: database for the interpretation of phenotype-
linked plausibly pathogenic sequence and copy-number variation. Nucleic
Acids Res. 42, D993–D1000 (2014).
58. McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122
(2016).
59. 1000 Genomes Project Consortium. et al. A global reference for human
genetic variation. Nature 526, 68–74 (2015).
60. Ramu, A. et al. DeNovoGear: de novo indel and point mutation discovery and
phasing. Nat. Methods 10, 985–987 (2013).
61. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans.
Nature 536, 285–291 (2016).
62. Manichaikul, A. et al. Robust relationship inference in genome-wide
association studies. Bioinformatics 26, 2867–2873 (2010).
63. Van Hout, C. V., et al. Exome sequencing and characterization of 49,960
individuals in the UK Biobank. Nature 586, 749–756 (2020).
64. Jia, T., Munson, B., Allen, H. L., Ideker, T. & Majithia, A. R. Thousands of
missing variants in the UK Biobank are recoverable by genome
realignment. Ann. Hum. Genet. 84, 214–220 (2020).
65. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD:
predicting the deleteriousness of variants throughout the human genome.
Nucleic Acids Res. 47, D886–D894 (2019).
66. MacArthur, D. G. et al. A systematic survey of loss-of-function variants in
human protein-coding genes. Science 335, 823–828 (2012).
67. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26
(2011).
68. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and
genomic data. Nature 562, 203–209 (2018).
69. Martin, H. C. & Gardner, E. J. DDD_chrX: code release for DDD chrX paper.
https://doi.org/10.5281/zenodo.4133895 (2020).
Acknowledgements
We thank the DDD families for participating, the DDD clinicians for recruiting patients, the
Sanger Sample Management and Sequencing pipelines teams for generating the data, the
Sanger Human Genome Informatics team for helping to process the exome data, and Nicola
Whiffin for helpful comments on the manuscript. The study was approved by the UK
Research Ethics Committee (10/H0305/83, granted by the Cambridge South Research Ethics
Committee and GEN/284/12, granted by the Republic of Ireland Research Ethics Com-
mittee). This work has been conducted using the UK Biobank Resource under Application
Number 44165. The DDD study presents independent research commissioned by the
Health Innovation Challenge Fund (grant HICF-1009-003), a parallel funding partnership
between the Wellcome Trust and the UK Department of Health, and the Wellcome Trust
Sanger Institute (grant WT098051). The views expressed in this publication are those of the
author(s) and not necessarily those of the Wellcome Trust or the UK Department of Health.
The study has UK Research Ethics Committee approval (10/H0305/83, granted by the
Cambridge South Research Ethics Committee and GEN/284/12, granted by the Republic of
Ireland Research Ethics Committee). The research team acknowledges the support of the
National Institutes for Health Research, through the Comprehensive Clinical Research
Network. This study makes use of DECIPHER (http://decipher.sanger.ac.uk), which is
funded by the Wellcome Trust.
Author contributions
H.C.M. analysed the DDD data and drafted the manuscript together with M.E.H. who
conceived and supervised the study. J.K. and K.E.S. assisted with the filtering of DNMs in
the DDD study and modelling of mutation rates. A.S., N.A. and J.M. contributed to
analyses of the DDD exome data. R.Y.E. and G.G. conducted quality control on the DDD
exome data. E.J.G. and M.D.C.N. analysed the UK Biobank exome data. A.L.T.T.
examined clinical features of patients. M.E.K.N processed the chip genotype data and
constructed polygenic scores. C.F.W., D.R.F. and H.V.F. provided clinical and analytical
supervision.
Competing interests
M.E.H. is a co-founder of, consultant to, and holds shares in Congenica Ltd., a genetics
diagnostics company. J.F.M. is an employee of Illumina Inc. A.L.T.T. is an employee of
Genomics England. The other authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-20852-3.
Correspondence and requests for materials should be addressed to H.C.M.
Peer review information Nature Communications thanks Lisenka Vissers and the other,
anonymous, reviewer for their contribution to the peer review of this work. Peer reviewer
reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20852-3 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:627 | https://doi.org/10.1038/s41467-020-20852-3 | www.nature.com/naturecommunications 11
Deciphering Developmental Disorders Study
Silvia Borras11, Caroline Clark11, John Dean11, Zosia Miedzybrodzka11, Alison Ross11, Stephen Tennant11,
Tabib Dabir12, Deirdre Donnelly12, Mervyn Humphreys12, Alex Magee12, Vivienne McConnell12, Shane McKee12,
Susan McNerlan12, Patrick J. Morrison12, Gillian Rea12, Fiona Stewart12, Trevor Cole13, Nicola Cooper13,
Lisa Cooper-Charles13, Helen Cox13, Lily Islam13, Joanna Jarvis13, Rebecca Keelagher13, Derek Lim13,
Dominic McMullan13, Jenny Morton13, Swati Naik13, Mary O’Driscoll13, Kai-Ren Ong13, Deborah Osio13,
Nicola Ragge13, Sarah Turton13, Julie Vogt13, Denise Williams13, Simon Bodek14, Alan Donaldson14, Alison Hills14,
Karen Low14, Ruth Newbury-Ecob14, Andrew M. Norman14, Eileen Roberts14, Ingrid Scurr14, Sarah Smithson14,
Madeleine Tooley14, Steve Abbs4, Ruth Armstrong4, Carolyn Dunn4, Simon Holden4, Soo-Mi Park4,
Joan Paterson4, Lucy Raymond4, Evan Reid4, Richard Sandford4, Ingrid Simonic4, Marc Tischkowitz4,
Geoff Woods4, Lisa Bradley15, Joanne Comerford15, Andrew Green15, Sally Lynch15, Shirley McQuaid15,
Brendan Mullaney15, Jonathan Berg16, David Goudie16, Eleni Mavrak16, Joanne McLean16, Catherine McWilliam16,
Eleanor Reavey16, Tara Azam10, Elaine Cleary10, Andrew Jackson10, Wayne Lam10, Anne Lampe10,
David Moore10, Mary Porteous10, Emma Baple17, Júlia Baptista17, Carole Brewer17, Bruce Castle17,
Emma Kivuva17, Martina Owens17, Julia Rankin17, Charles Shaw-Smith17, Claire Turner17, Peter Turnpenny17,
Carolyn Tysoe17, Therese Bradley18, Rosemarie Davidson18, Carol Gardiner18, Shelagh Joss18, Esther Kinning18,
Cheryl Longman18, Ruth McGowan18, Victoria Murday18, Daniela Pilz18, Edward Tobias18, Margo Whiteford18,
Nicola Williams18, Angela Barnicoat19, Emma Clement19, Francesca Faravelli19, Jane Hurst19, Lucy Jenkins19,
Wendy Jones19, V.K.Ajith Kumar19, Melissa Lees19, Sam Loughlin19, Alison Male19, Deborah Morrogh19,
Elisabeth Rosser19, Richard Scott19, Louise Wilson19, Ana Beleza20, Charu Deshpande20, Frances Flinter20,
Muriel Holder20, Melita Irving20, Louise Izatt20, Dragana Josifova20, Shehla Mohammed20, Aneta Molenda20,
Leema Robert20, Wendy Roworth20, Deborah Ruddy20, Mina Ryten20, Shu Yau20, Christopher Bennett21,
Moira Blyth21, Jennifer Campbell21, Andrea Coates21, Angus Dobbie21, Sarah Hewitt21, Emma Hobson21,
Eilidh Jackson21, Rosalyn Jewell21, Alison Kraus21, Katrina Prescott21, Eamonn Sheridan21, Jenny Thomson21,
Kirsty Bradshaw22, Abhijit Dixit22, Jacqueline Eason22, Rebecca Haines22, Rachel Harrison22, Stacey Mutch22,
Ajoy Sarkar22, Claire Searle22, Nora Shannon22, Abid Sharif22, Mohnish Suri22, Pradeep Vasudevan23,
Natalie Canham24, Ian Ellis24, Lynn Greenhalgh24, Emma Howard24, Victoria Stinton24, Andrew Swale24,
Astrid Weber24, Siddharth Banka25, Catherine Breen25, Tracy Briggs25, Emma Burkitt-Wright25,
Kate Chandler25, Jill Clayton-Smith25, Dian Donnai25, Sofia Douzgou25, Lorraine Gaunt, Elizabeth Jones25,
Bronwyn Kerr25, Claire Langley25, Kay Metcalfe25, Audrey Smith25, Ronnie Wright25, David Bourn26,
John Burn26, Richard Fisher26, Steve Hellens26, Alex Henderson26, Tara Montgomery26, Miranda Splitt26,
Volker Straub26, Michael Wright26, Simon Zwolinski26, Zoe Allen27, Birgitta Bernhard27, Angela Brady27,
Claire Brooks27, Louise Busby27, Virginia Clowes27, Neeti Ghali27, Susan Holder27, Rita Ibitoye27,
Emma Wakeling27, Edward Blair28, Jenny Carmichael28, Deirdre Cilliers28, Susan Clasper28, Richard Gibbons28,
Usha Kini28, Tracy Lester28, Andrea Nemeth28, Joanna Poulton28, Sue Price28, Debbie Shears28,
Helen Stewart28, Andrew Wilkie28, Shadi Albaba29, Duncan Baker29, Meena Balasubramanian29,
Diana Johnson29, Michael Parker29, Oliver Quarrell29, Alison Stewart29, Josh Willoughby29, Charlene Crosby30,
Frances Elmslie30, Tessa Homfray30, Huilin Jin30, Nayana Lahiri30, Sahar Mansour30, Karen Marks30,
Meriel McEntagart30, Anand Saggar30, Kate Tatton-Brown30, Rachel Butler31,32, Angus Clarke31,32,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20852-3
12 NATURE COMMUNICATIONS |          (2021) 12:627 | https://doi.org/10.1038/s41467-020-20852-3 | www.nature.com/naturecommunications
Sian Corrin31,32, Andrew Fry31,32, Arveen Kamath31,32, Emma McCann31,32, Hood Mugalaasi31,32,
Caroline Pottinger31,32, Annie Procter31,32, Julian Sampson31,32, Francis Sansbury31,32, Vinod Varghese31,32,
Diana Baralle33,34,35, Alison Callaway33,34,35, Emma J. Cassidy33,34,35, Stacey Daniels33,34,35,
Andrew Douglas33,34,35, Nicola Foulds33,34,35, David Hunt33,34,35, Mira Kharbanda33,34,35,
Katherine Lachlan33,34,35, Catherine Mercer33,34,35, Lucy Side33,34,35, I. Karen Temple33,34,35 &
Diana Wellesley33,34,35
11North of Scotland Medical Genetics Service, NHS Grampian, Aberdeen, UK. 12Northern Ireland Regional Genetics Centre, Belfast Health and
Social Care Trust, Belfast City Hospital, Belfast, UK. 13West Midlands Regional Genetics Service, Birmingham Women’s NHS Foundation Trust,
Birmingham Women’s Hospital, Birmingham, UK. 14Bristol Genetics Service, University Hospitals Bristol NHS Foundation Trust, St Michael’s
Hospital, Bristol, UK. 15National Centre for Medical Genetics, Our Lady’s Children’s Hospital, Dublin, Ireland. 16East of Scotland Regional Genetics
Service, NHS Tayside, Ninewells Hospital, Dundee, UK. 17Peninsula Clinical Genetics Service, Royal Devon and Exeter NHS Foundation Trust, Royal
Devon & Exeter Hospital (Heavitree), Exeter, UK. 18West of Scotland Regional Genetics Service, NHS Greater Glasgow and Clyde, Yorkhill Hospital,
Glasgow, UK. 19North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond
Street Hospital, London, UK. 20South East Thames Regional Genetics Centre, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London,
UK. 21Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK. 22Nottingham Regional
Genetics Service, City Hospital Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK. 23Leicestershire Genetics Centre, University
Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK. 24Merseyside and Cheshire Genetics Service, Liverpool Women’s NHS
Foundation Trust, Royal Liverpool Children’s Hospital Alder Hey, Liverpool, UK. 25Manchester Centre for Genomic Medicine, Central Manchester
University Hospitals NHS Foundation Trust, St Mary’s Hospital, Manchester, UK. 26Northern Genetics Service, Institute of Human Genetics,
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 27North West Thames Regional Genetics Service, London North
West University Healthcare NHS Trust, St Mark’s Hospital, Harrow, UK. 28Oxford Regional Genetics Service, Oxford Radcliffe Hospitals NHS Trust,
Oxford, UK. 29Sheffield Regional Genetics Services, Sheffield Children’s NHS Trust, Sheffield, UK. 30South West Thames Regional Genetics Centre,
St George’s Healthcare NHS Trust, St George’s, University of London, London, UK. 31Institute of Medical Genetics, University Hospital of Wales,
Cardiff, UK. 32Department of Clinical Genetics, Glan Clwyd Hospital, Rhyl, UK. 33Wessex Clinical Genetics Service, University Hospital
Southampton, Princess Anne Hospital, Southampton, UK. 34Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury
District Hospital, Salisbury, UK. 35Faculty of Medicine, University of Southampton, Southampton, UK.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20852-3 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:627 | https://doi.org/10.1038/s41467-020-20852-3 | www.nature.com/naturecommunications 13
